Crimson Publishers Publish With Us Reprints e-Books Video articles


Interventions in Obesity & Diabetes

GLP-1 Obesity and Diabetes Gerald H Tomkin and Daphne Owens

  • Open or CloseGerald HT*

    Coillancarraig Lodge, Rocky Valley Drive, Kilmacanogue, Co Wicklow, Ireland

    *Corresponding author:Gerald H Tomkin, Coillancoraig Lodge, Rocky valley Drive, Kilmacanogue, Ireland

Submission: March 12, 2019Published: June 20, 2019

DOI: 10.31031/IOD.2019.03.000553

ISSN : 2578-0263
Volume3 Issue1


Obesity is commonly associated with type 2 diabetes. Weight reduction in obese subjects is effective in both preventing the onset of type 2 diabetes and in reversing the condition once present. GLP1 agonists have been shown to inhibit appetite both by delaying gastric emptying and increasing saiety at a central level. These drugs have been shown to delay the onset of type 2 diabetes, to reverse diabetes and to lower blood sugar in patients with Type 2 diabetes. Development of these drugs has resulted in prolongation of absorption so that they may be given by subcutaneous injections and more recently reports of an oral preparation of semaglutide that has similar efficacy to the subcutaneous preparation have appeared. The drugs have been shown to result in cardiovascular protection.

Keywords: Diabetes; Extendin 1,2,3,4; GLP-1 Receptor; DPP-4; Oral Semaglutide; Obesity

Abbreviations: VIP: Vasoactive Intestinal Peptide

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137